VRAX logo

VRAX

Virax Biolabs Group LimitedNASDAQHealthcare
$0.17-12.18%ClosedMarket Cap: $755,500

As of 2026-04-06

Valuation

View Details

P/E (TTM)

PEG

P/B

0.14

P/S

222.19

EV/EBITDA

0.39

DCF Value

$1.26

FCF Yield

-914.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

-8774.5%

Operating Margin

-196566.7%

Net Margin

-189001.7%

ROE

-102.5%

ROA

-98.8%

ROIC

-99.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q2 2026$1.6K$-2.3M$-0.49
Q4 2025$1.4K$-3.3M$-0.76
FY 2025$6.3K$-6.1M$-1.95
Q2 2025$5.0K$-2.8M$-0.89

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$1.00

Target (Median)

$1.00

Target Range

$1.00 - $1.00

0 Strong Buy1 Buy0 Hold0 Sell0 Strong Sell
HC Wainwright & Co.Buy
2026-01-09

Trading Activity

Insider Trades

View All
HAIGHT NELSON Mdirector
SellTue Mar 31
HAIGHT NELSON Mdirector
SellTue Mar 31
McCracken Nigel Williamdirector, officer: Chief Operating Officer
SellFri Mar 20
McCracken Nigel Williamdirector, officer: Chief Operating Officer
SellFri Mar 20
McCracken Nigel Williamdirector, officer: Chief Operating Officer
SellFri Mar 20

Company Info

Sector

Healthcare

Industry

Country

GB

Exchange

NASDAQ

Beta

1.60

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Peers